anxiety; bronchitis; influenza; knee problems; sinusitis; hypoglycemia; high cholesterol; hormones; irritable bowel syndrome (IBS); heartburn; attention deficit disorder (ADD); insomnia; skin problems; varicella type rash; shingles and other zoster related injuries/herpes zoster/rash/painful; zoster vaccine live (ZOSTAVAX) administered to a 32-year-old patient; Information has been received from a lawyer, regarding a case in litigation, and refers to a patient (pt) of unknown age and gender. No information about the pt's medical history, concurrent conditions or concomitant medications was provided. In 2012, the pt was administered zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not provided) by a healthcare provider at a family medicine laboratory for the long-term prevention of shingles and zoster-related conditions. Subsequently, on unknown dates, the pt was treated by a healthcare provider at the family medicine laboratory for the following injuries resulting from the pt's zoster vaccine live (ZOSTAVAX) use: shingles and other zoster related conditions. The outcome of the events was not provided. The reporter considered shingles and other zoster related conditions to be related to zoster vaccine live (ZOSTAVAX).  Follow up (FU) information has been received on 26-JAN-2021 from a lawyer via a Plaintiff Fact Sheet, regarding a case in litigation, and refers to a 42-year-old female pt. The pt smoked cigarettes from 1993 to 2007, 1 once a day on average. She was diagnosed with chickenpox in or about 1974, at the approx. age of 6 years old. The pt had never received a chickenpox vaccine. The pt was disabled (reported as "disable" in the employment history, with no dates provided). The pt filed for social security benefits for mental health problems in 2003; granted. In the 7 years preceding her zoster vaccine live (ZOSTAVAX)-vaccination to the present, the pt received inpatient or outpatient care for the following reasons (approx. dates of care/treatment given): primary care, from 2001 to present; bronchitis (onset date, treatment, outcome and causality unknown), 24-MAR-2013 - just one time; influenza (onset date, treatment, outcome and causality unknown), 13-JAN-2014 - just one time; hypothyroidism, from 11-NOV-2015 to 09-FEB-2017; knee problems (onset date, treatment, outcome and causality unknown), from 29-NOV-2017 to present; sinusitis (onset date, treatment, outcome and causality unknown), from 29-DEC-2017 to present; skin problems (onset date, treatment, outcome and causality unknown), from 21-MAR-2015 to present; psychiatric medical conditions, from 2001 to present. Medical conditions other than those alleged to be caused by zoster vaccine live (ZOSTAVAX), for which the pt required hospitalization or recurrent medical care and treatment or medication at any time during the 7 years preceding her zoster vaccine live (ZOSTAVAX) vaccination to present, included (approx. dates of care/treatment given): bronchitis, 24-MAR-2013 - just one time; influenza, 13-JAN-2014 - just one time; hypothyroidism, from 2010 to present; knee problems, from 29-NOV-2017 to present; sinusitis, from 29-DEC-2017 to present; skin problems, from 21-MAR-2015 to present; psychiatric medical conditions, from 2001 to present; hypoglycemia (onset date, outcome and causality unknown), from 2016 to present; high cholesterol (onset date, outcome and causality unknown), from October 2019 to present; hormones (onset date, outcome and causality unknown), from 2012 to present; shingles, from 2006 to present (hence, the event of herpes zoster considered to be a progression of disease); irritable bowel syndrome (IBS) (onset date, outcome and causality unknown), from 01-AUG-2020 to present; heartburn (onset date, outcome and causality unknown) and anxiety, both from January 2012 to present. Prescription medications that the pt had taken on a regular basis in the 7 years preceding her zoster vaccine live (ZOSTAVAX) vaccination to the present included (approximate dates of use given): linaclotide (LINZESS), from 01-AUG-2020 to present, for IBS; omeprazole (reported as "ameprazole"), from January 2012 to present, for heartburn; clonazepam (KLONOPIN), from January 2012 to present, for anxiety; methylphenidate hydrochloride (RITALIN), from 02-OCT-2019 to present, for attention deficit disorder (ADD) (onset date, outcome and causality unknown); vortioxetine hydrobromide (TRINTELLIX), from 2016 to present, for bipolar depression; metformin (reported as "Medphormine"), from 2016 to present, for hypoglycemia; trazodone, from July 2020 to present, for insomnia (onset date, outcome and causality unknown); rosuvastatin calcium (CRESTOR), from October 2019 to present, for high cholesterol; ethinyl estradiol (+) levonorgestrel (AMETHYST), from 2012 to present, for hormones; valacyclovir hydrochloride (VALTREX), from 2017 to present, for shingles; valacyclovir (reported as "Valazyclovir"), from March 2006 to 2017, for shingles; prazosin, from 2010 to present, for post-traumatic stress disorder (PTSD) and nightmares; naltrexone hydrochloride (REVIA), from 2015 to present, for bipolar disorder; lamotrigine (LAMICTAL) and bupropion hydrochloride (WELLBUTRIN), both from 2006 to present, both for bipolar disorder; levothyroxine, from 2010 to present, for hypothyroidism. Before receiving zoster vaccine live (ZOSTAVAX), the pt experienced shingles, diagnosed on 06-MAR-2006 by a physician at a family medicine facility, treatment received: ointments (unspecified) and oral oils (unspecified) for pain (reported as "acyclovir"). At any time in the 7 years preceding her alleged zoster vaccine live (ZOSTAVAX)-related injury to the present, the pt used or took the following medications: steroids or corticosteroids, for sinus infection, taken in or about 2008. On 01-FEB-2011, the pt was administered zoster vaccine live (ZOSTAVAX) in the left arm by a physician at a family medicine facility. The pt received a written prescription for zoster vaccine live (ZOSTAVAX) from the physician. The pt did not recall if she had received any written or oral instruction or information about zoster vaccine live (ZOSTAVAX) before receiving it. The pt claimed that she suffered the following physical injuries related to her zoster vaccine live (ZOSTAVAX) administration: shingles (herpes zoster), and varicella type rash. She experienced shingles all around her body. The pt first became aware of these injuries on 01-MAR-2011, and of varicella type rash in or about November 2011, because she noticed some kind of rash all around her body, it was very painful, so she went to see her doctor and he said she had shingles. The pt was diagnosed by the physician with shingles on or about 01-JUN-2011. In connection with the injuries alleged to be have been caused by zoster vaccine live (ZOSTAVAX), the pt was prescribed the following medications/received the following treatments (approx. dates of treatment given): creams (unspecified) and oral pills (unspecified) for pain, on or about 01-JUN-2011. In or about November 2011, a test ordered and performed by the physician at the family medicine facility to determine if the rash was wild type or vaccine strain varicella zoster virus. The result of the test was vaccine strain varicella zoster virus. In or about November 2011, the physician at the family medicine facility told the pt that she had vaccine strain varicella zoster virus. The pt claimed that her receipt of zoster vaccine live (ZOSTAVAX) caused or aggravated the following psychiatric and/or psychological conditions (other than pain and suffering and emotional distress): anxiety, diagnosed in or about October 2014 by a physician. The outcome of the events of shingles (herpes zoster) and varicella type rash was not provided. The reporter considered the events of shingles (herpes zoster) and varicella type rash to be related to zoster vaccine live (ZOSTAVAX).